Open ‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression

ConclusionsBrexanolone was well tolerated and demonstrated activity in severe PPD. Larger, double‐blind trials are needed for further evaluation.

Source: Human Psychopharmacology: Clinical and Experimental - March 30, 2017 Category: Psychiatry Authors: Stephen J. Kanes, Helen Colquhoun, James Doherty, Shane Raines, Ethan Hoffmann, David R. Rubinow, Samantha Meltzer ‐Brody Tags: SHORT COMMUNICATION Source Type: research